Incyte (INCY) Misses Q4 EPS by 7c
Get Alerts INCY Hot Sheet
Price: $126.75 -0.98%
Revenue Growth %: +7.3%
Financial Fact:
Basic (in dollars per share): 0.2
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.3%
Financial Fact:
Basic (in dollars per share): 0.2
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q4 EPS of $0.40, $0.07 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $468 million versus the consensus estimate of $485.8 million.
2019 Financial Guidance
The Company has provided full year 2019 financial guidance, as detailed below.
| � | � | � | � |
| � | � | � | 2019 |
| GAAP and Non-GAAP Jakafi net product revenues | � | � | $1,580 - $1,650 million |
| GAAP and Non-GAAP Iclusig net product revenues | $90 - $100 million | ||
| � | |||
| GAAP Cost of product revenues | $112 - $117 million | ||
| Non-GAAP Cost of product revenues(1) | $90 - $95 million | ||
| � | |||
| GAAP Research and development expenses | $1,185 - $1,255 million | ||
| Non-GAAP Research and development expenses(2) | $1,030 - $1,100 million | ||
| � | |||
| GAAP Selling, general and administrative expenses | $471 - $521 million | ||
| Non-GAAP Selling, general and administrative expenses(3) | $420 - $470 million | ||
| � | |||
| GAAP Change in fair value of acquisition-related contingent consideration | $30 million | ||
| Non-GAAP Change in fair value of acquisition-related contingent consideration(4) | � | � | $0 million |
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share